首页|期刊导航|中医肿瘤学杂志|林丽珠辨治表皮生长因子受体酪氨酸激酶抑制剂相关不良反应临证经验撷英

林丽珠辨治表皮生长因子受体酪氨酸激酶抑制剂相关不良反应临证经验撷英OA

Lin Lizhu's Clinical Experience in Treating Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Related Adverse Reactions Based on Syndrome Differentiation

中文摘要英文摘要

本文总结林丽珠教授辨治表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)相关不良反应的临证经验.林丽珠教授认为"正虚邪伏,毒药引动"是EGFR-TKI不良反应的核心病机,肺癌患者正气亏虚、邪气内伏,药物毒性引动伏邪而发为皮疹、口疮、腹泻等药毒诸症;治疗以"解毒透邪,扶益正气"为原则,针对不同性质伏邪,施以透邪祛邪之法,同时固护肺脾肝肾之本.本文从伏邪角度为靶向药所致药毒的辨治提供思路,为中医药协同减毒提供参考.

This article summarizes Professor Lin Lizhu's clinical experience in treating epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)-related adverse reactions based on syndrome differentiation.It is believed that"healthy qi deficiency with latent pathogen as the foundation,triggered by drug toxicity"constitutes the core pathogenesis of EGFR-TKI-related adverse reactions.In lung cancer patients,healthy qi deficiency and internal latent pathogens exist,and the toxicity of drugs triggers latent pathogens,leading to various symptoms of drug toxicity such as rash,oral ulcers,and diarrhea.The treatment principle is"eliminating toxins and expelling pathogens,and reinforcing healthy qi".Based on the specific nature of the latent pathogens,methods are applied to expel pathogens,while simultaneously consolidating and protecting the fundamentals of lung,spleen,liver,and kidney.This approach provides insights for the treatment of targeted therapy-induced drug toxicity from the perspective of latent pathogens,and offers a reference for the synergistic attenuation of toxicity with traditional Chinese medicine.

姚衍竹;林丽珠;李雪维;黄俊杰;林洁涛;綦向军;王景锐;郑鑫泽;李晏龙;余玲

广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学第一附属医院肿瘤中心,广东 广州 510405广州中医药大学第一临床医学院,广东 广州 510405重庆医科大学附属第二医院中西医结合医学中心,重庆 404100广州中医药大学第一附属医院肿瘤中心,广东 广州 510405广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学第七临床医学院,广东 深圳 518033广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学第一临床医学院,广东 广州 510405广州中医药大学第一附属医院肿瘤中心,广东 广州 510405

医药卫生

表皮生长因子受体酪氨酸激酶抑制剂不良反应名医经验皮疹口疮腹泻肝功能受损间质性肺疾病

epidermal growth factor receptor-tyrosine kinase inhibitoradverse reactionsclinical experience of renowned physiciansrashoral ulcerdiarrhealiver function impairmentinterstitial lung disease

《中医肿瘤学杂志》 2026 (4)

57-64,8

"广东特支计划"省卫生健康委(卫生健康人才)领军人才项目(编号:0720240115)国家中医药传承创新中心重点病种(肺癌)中国中医药联合研究生院科教专项(编号:CI2023C030LH).

10.19811/j.cnki.ISSN2096-6628.2026.07.008

评论